Triple-Drug cocktail aims to boost remission in acute myeloid leukemia
NCT ID NCT05654194
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial is testing whether a combination of three drugs—azacitidine, venetoclax, and ATRA—can safely and effectively treat adults newly diagnosed with acute myeloid leukemia (AML). The drugs work together to stop cancer cell growth by demethylating DNA, promoting cell differentiation, and killing cancer cells. Participants receive the combination in cycles as induction, consolidation, and maintenance therapy. The main goal is to see how many patients achieve complete remission after the first cycle.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
azacitidine, venetoclax, and ATRA (all-trans retinoic acid)
What this could lead to
If successful, this three-drug combination could offer a more effective initial treatment for acute myeloid leukemia, potentially leading to higher remission rates without the need for intensive chemotherapy.
What could go wrong
This is a single-arm, early-phase trial with a small number of participants, so results may not apply to all AML patients. The combination may cause significant side effects, and it is not yet known if it improves long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the First Affiliated Hospital of Soochow University
Suzhou, China